Beam Therapeutics Inc
$ 26.74
14.42%
03 Dec - close price
- Market Cap 2,713,440,000 USD
- Current Price $ 26.74
- High / Low $ 26.85 / 23.30
- Stock P/E N/A
- Book Value 9.80
- EPS -5.05
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.47 %
- 52 Week High 35.25
- 52 Week Low 13.53
About
Beam Therapeutics Inc. is an innovative biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic therapies for patients with serious and often life-threatening diseases. By utilizing advanced gene-editing technologies, particularly base editing, Beam aims to create targeted treatments that address the root causes of genetic disorders. The company's robust pipeline showcases its commitment to transforming patient outcomes through precision medicine, positioning it as a leader in the burgeoning field of genetic therapeutics. As it advances its clinical programs, Beam is well-equipped to meet the evolving needs of patients and healthcare providers alike.
Analyst Target Price
$45.93
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-05 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-08 | 2023-08-08 | 2023-05-10 | 2023-02-28 |
| Reported EPS | -1.1 | -1 | -1.2421 | -1.09 | -1.17 | -1.11 | -1.21 | 1.73 | -1.22 | -1.08 | -1.33 | -0.54 |
| Estimated EPS | -1.03 | -1.11 | -1.1714 | -1.2158 | -1.16 | -1.13 | -1.42 | -1.01 | -1.36 | -1.42 | -1.34 | -1.33 |
| Surprise | -0.07 | 0.11 | -0.0707 | 0.1258 | -0.01 | 0.02 | 0.21 | 2.74 | 0.14 | 0.34 | 0.01 | 0.79 |
| Surprise Percentage | -6.7961% | 9.9099% | -6.0355% | 10.3471% | -0.8621% | 1.7699% | 14.7887% | 271.2871% | 10.2941% | 23.9437% | 0.7463% | 59.3985% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BEAM
2025-10-12 06:48:16
Jefferies Financial Group has issued a "buy" rating for Beam Therapeutics (NASDAQ:BEAM) in a recent research report. This follows a previous "strong-buy" upgrade from Cantor Fitzgerald. The article also details recent insider stock sales and changes in institutional investor holdings for Beam Therapeutics.
2025-10-12 06:13:13
HC Wainwright has reaffirmed its "buy" rating for Beam Therapeutics (NASDAQ:BEAM). The article details recent insider transactions, including a sale of 48,374 shares by Fmr Llc, and outlines institutional investors' activity in the company's stock. It also provides a company profile for Beam Therapeutics, highlighting its focus on developing precision genetic medicines.
2025-10-11 17:08:03
Beam Therapeutics (BEAM) has seen a resurgence in its stock price following fresh Buy ratings from major banks like Jefferies and HC Wainwright, positive pipeline updates, and increased institutional investor activity. Despite a challenging few years, the company is now trading at $26.32 with analysts suggesting a fair value of over $45, driven by projections of aggressive revenue expansion and margin improvements. However, its high price-to-sales ratio compared to industry averages indicates potential caution regarding whether the optimism is already fully priced in.
2025-06-03 07:00:00
Beam Therapeutics announced that the U.S. FDA has granted orphan drug designation to BEAM-101 for the treatment of sickle cell disease (SCD). This designation provides potential benefits for the drug's development and reflects the importance of new treatment options for the debilitating condition. Clinical data from the BEACON trial for BEAM-101 has shown promising results in increasing fetal hemoglobin and reducing sickle hemoglobin.
2025-03-10 06:00:00
Beam Therapeutics announced positive initial data from its Phase 1/2 trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD), demonstrating the first clinical genetic correction of a disease-causing mutation. BEAM-302 achieved durable, dose-dependent increases in total and functional AAT and reductions in mutant Z-AAT, exceeding the protective therapeutic threshold and showing a well-tolerated safety profile. These results represent a significant breakthrough, offering a potential one-time therapy to address the root cause of AATD and improve both liver and lung disease manifestations.
2025-01-13 07:00:00
Beam Therapeutics announced significant progress in its hematology and genetic disease franchises, outlining key anticipated catalysts for 2025. The company shared updates on its BEACON trial for sickle cell disease, initial data expectations for BEAM-302 in alpha-1 antitrypsin deficiency, and the planned initiation of dosing for BEAM-301 in glycogen storage disease type 1a. Beam Therapeutics also confirmed a strong financial position, with its cash runway expected to extend into 2027, including commercial readiness activities for BEAM-101.
